Edesa Biotech EBITDA
¿Qué es el EBITDA de Edesa Biotech?
El EBITDA de Edesa Biotech, Inc. es -$20.91
¿Cuál es la definición de EBITDA?
El EBITDA es la ganancia de una compañía antes de intereses, impuestos, depreciación y amortización y es una medida contable calculada usando las ganancias netas de la compañía, antes de que se resten los gastos de interés, los impuestos, la depreciación y la amortización, como un proxy de la rentabilidad operativa actual de la compañía.
Although EBITDA is not a financial measure recognized in generally accepted accounting principles, it is widely used in many areas of finance when assessing the performance of a company, such as securities analysis. It is intended to allow a comparison of profitability between different companies, by discounting the effects of interest payments from different forms of financing (by ignoring interest payments), political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill). EBITDA is a financial measurement of cash flow from operations that is widely used in mergers and acquisitions of small businesses and businesses in the middle market. It is not unusual for adjustments to be made to EBITDA to normalize the measurement allowing buyers to compare the performance of one business to another.
EBITDA de compañías en Sector Health Care en NASDAQ en comparadas con Edesa Biotech
¿Qué hace Edesa Biotech?
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Empresas con ebitda similar a Edesa Biotech
- Sensorion SAS tiene EBITDA de -€21.02
- Lifeist Wellness tiene EBITDA de -CAD$21.01
- Zagg Inc tiene EBITDA de -$20.98
- Tree House Education & Accessories tiene EBITDA de -₨20.95
- China International Development tiene EBITDA de -HKD$20.94
- Nexus Minerals tiene EBITDA de -AUD$20.93
- Edesa Biotech tiene EBITDA de -$20.91
- Invinity Systems tiene EBITDA de -£20.91
- Novatti tiene EBITDA de -AUD$20.90
- Mohawk tiene EBITDA de -$20.89
- Asia Pioneer Entertainment tiene EBITDA de -HKD$20.88
- Mednow tiene EBITDA de -CAD$20.87
- Mednow tiene EBITDA de -CAD$20.87